Industry Briefs: July 9, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: July 9, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

AstraZeneca has completed the previously announced sale of the assets of its subsidiary, Aptium Oncology. Read More

Cancer Research Technology (CRT), the commercial arm of Cancer Research UK, and ADC Therapeutics Sarl (ADCT) have signed agreements to develop antibody drug conjugates using CRT’s antibodies and peptides, and ADCT’s linker chemistries and proprietary pyrrolobenzodiazepines technology. Read More

The CureBeta R&D collaboration between Evotec and Harvard University has entered into a strategic alliance with Janssen Pharmaceuticals. Read More

Hal Allergy has expanded its GMP contract manufacturing activities for clinical-batch supply of both recombinant and viral products. Read More

Prokarium, a spin-out company of Cobra Biologics, has acquired oral-vaccine technology from Emergent BioSolutions. Read More

Sanofi has agreed to divest its 19.3% stake in the Yves Rocher Group. Read More

Spectrum Pharmaceuticals has provided an additional extension of the offer period in connection with its tender offer to purchase all of the outstanding shares of common stock of Allos Therapeutics for $1.82 per share in cash. Read More

People News

Affymax has named Michael Holfinger vice-president of manufacturing and CMC development. Read More

Arena Pharmaceuticals has appointed Craig M. Audet to executive officer as senior vice-president, operations, and head of global regulatory affairs. Read More

Chiral Technologies has appointed Jauh-Tzuoh Lee as technology manager. Read More

Ricerca Biosciences named G. Lynn Miesel technical director. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here